1. A method of treating lupus erythematosus, comprising administering to a subject in need thereof a therapeutically effective amount of a human monoclonal antibody or antigen binding portion thereof specifically binding to M-CSF (macrophage colony stimulating factor) .2. The method of claim 1, wherein said antibody or antigen binding site has at least one of the following properties: a) binds to human secreted M-CSF isoforms and membrane-bound M-CSF isoforms； b) have M-CSF selectivity of at least 100 times greater than its selectivity for GM-CSF (granulocyte macrophage colony stimulating factor) or G-CSF (granulocyte colony stimulating factor)； c) bind to M-CSF with K (equilibrium dissociation constant) 1.0 × 10M or less ； d) have a dissocial velocity ation (k) for M-CSF of less than 2.0 × 10cili； ilie) bind to human M-CSF in the presence of human c-fms.3. The method of claim 2, wherein said antibody or antigen binding site blocks c-fms binding and binds to M-CSF with K1.0 × 10M or less. The method of claim 1, wherein the antibody or antigen binding site has at least one property selected from the group consisting of the following: a) cross-competes for binding to M-CSF with an antibody selected from the group consisting of: antibodies 252, 88 , 100, 3.8.3, 2.7.3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser , 8.10.3C-Ser, 8.10.3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10 .3-Ser, 8.10.3-CG4, 8.10.3FG1 and 9.14.4G1； b) compete for binding to M-CSF with an antibody selected from the group consisting of: 252, 88, 100, 3.8.3, 2.7. 3, 1.120.1, 9.14.4I, 8.10.3F, 9.7.2IF, 9.14.4, 8.10.3, 9.7.2, 9.7.2C-Ser, 9.14.4C-Ser, 8.10.3C-Ser, 8.10. 3-CG2, 9.7.2-CG2, 9.7.2-CG4, 9.14.4-CG2, 9.14.4-CG4, 9.14.4-Ser, 9.7.2-Ser, 8.10.3-S1. Способ лечения волчанки, включающий введение субъекту, нуждающемуся в этом, терапевтически эффективного количества человеческого моноклонального антитела или его антигенсвязывающе
